Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 4

2(50.0%)

N/A

1(25.0%)

Phase 1

1(25.0%)

4Total

Phase 4(2)

N/A(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT01270139Not ApplicableCompleted

Plasmonic Nanophotothermal Therapy of Atherosclerosis

Role: collaborator

NCT01265615Phase 4Completed

Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients

Role: collaborator

NCT01436123Phase 1Terminated

Plasmonic Photothermal and Stem Cell Therapy of Atherosclerosis Versus Stenting

Role: collaborator

NCT01319188Phase 4Terminated

Ranibizumab and the Risk of Arterial Thromboembolic Events

Role: collaborator

All 4 trials loaded